SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Gynecologic Oncology Consultation — Gilda Radner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Gilda Radner |
|---|
| Date of birth | 1946-06-28 |
|---|
| Identifiers | MRN HR-ML026-SYN-TD; SSN (made up) 000-26-8821 |
|---|
| Document date | 1986-04-14 |
|---|
| Author | Sunita Varghese, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Suspected ovarian cancer in a 39-year-old comedian and actor with four weeks of bloating, early fullness, pelvic pain and urinary frequency on most days (ovarian cancer symptom index positive), a firm, fixed right adnexal mass and ascites on examination, a CA-125 of 1240 U/mL, and ovarian cancer in three relatives. Please see her within the week, confirm the diagnosis, and plan her primary treatment. [S]
Urgency: Urgent, within one week. [S]
Questions for the consultant:
- Does she have ovarian cancer, and what is its stage?
- Is she a candidate for primary cytoreductive surgery, or would chemotherapy before surgery be better?
- Which genetic tests should be done, on her blood and on the tumor, and what do the results mean for her and her family?
- What chemotherapy and maintenance treatment do you recommend after surgery, and what monitoring should primary care share?
- What should be done to prevent blood clots and to support her through treatment?
History of Present Illness
Ms. Radner, 39, is seen at the request of Dr. Marchand eight days after she first described four weeks of bloating, early fullness, pelvic pain and urinary frequency. Ultrasound the next day, CT the day after, and an omental core biopsy two days later have been completed. She eats small meals without vomiting and her bowels move daily. She has not carried a pregnancy to term and is not trying to conceive. Ovarian cancer affected her grandmother, an aunt and a cousin; she is of Ashkenazi Jewish ancestry. She is active and working, and she wants the facts and the plan plainly. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Gilda Radner was born on June 28, 1946, into a prosperous Detroit Jewish family; her paternal grandfather had emigrated from Lithuania. [D]
- She was the first person cast in Saturday Night Live, performed with its original troupe from 1975 to 1980, won an Emmy Award in 1978, and made several films, including three with Gene Wilder, whom she married in 1984. [D]
- Her father died of brain cancer when she was fourteen. Her grandmother, a cousin, and an aunt had all had ovarian cancer. [D]
- Her illness began with severe fatigue, which sources date to the filming of Haunted Honeymoon in England in 1985 or to early 1986; her internist attributed it to Epstein-Barr virus and told her not to worry. [D]
- Before her illness she and her husband tried to have a child; she had two miscarriages, one during the filming of Haunted Honeymoon in London, and an unsuccessful round of in vitro fertilization, after which doctors told her she was infertile. [D]
- During her Saturday Night Live years her lifelong insecurity about her appearance resurfaced in bouts of bulimia, which she later wrote about. [D]
6 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed |
R19.00 | S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation. |
| High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed |
C56.3 | S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D). |
| Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed |
C78.6 | S — Synthetic extent of disease on CT and biopsy. |
| Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed |
Z80.41 | S — Synthetic coding of her documented family history; the basis for genetic counseling. |
Physical Exam
Vital signs recorded on 1986-04-14; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Tired but composed; weight 58.9 kg; blood pressure 122/78, pulse 96 |
| Abdomen | Distended with shifting dullness; firm upper abdominal fullness consistent with omental disease; non-tender |
| Pelvic | Fixed, irregular masses in both adnexa, larger on the right; cervix normal; no rectovaginal nodularity |
| Lymph nodes | No supraclavicular, axillary or inguinal nodes |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1986-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | | | S |
| 1986-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | | | S |
Assessment
- High-grade serous carcinoma of both ovaries, clinical FIGO stage IIIC (C56.3). The biopsy and imaging establish high-grade serous carcinoma of Mullerian origin, clinical FIGO stage IIIC: disease in both ovaries, the omentum, the pelvic peritoneum and the right diaphragm, with no disease in the liver parenchyma, lungs or lymph nodes and no pleural effusion. She is fit, and the pattern of disease on CT can probably be removed completely, so primary cytoreductive surgery is preferred over chemotherapy first; the aim is no visible residual disease, which carries the best outlook. Surgery will be a laparotomy with hysterectomy, removal of both tubes and ovaries, total omentectomy, and removal of all visible peritoneal and diaphragmatic disease; lymph nodes will be removed only if enlarged. Pregnancy is not possible after this operation, which we discussed gently. Every woman with epithelial ovarian cancer should have germline genetic testing with counseling, and the tumor should be tested for BRCA1 and BRCA2 and homologous recombination deficiency, because the results guide maintenance treatment and, if a germline variant is found, testing for her blood relatives. Six cycles of carboplatin and paclitaxel every three weeks follow surgery; maintenance after a response is chosen from the genetic results, with a PARP inhibitor preferred if a BRCA1 or BRCA2 variant is found in the blood or the tumor; bevacizumab is not planned if all visible disease is removed. [S]
- Family history of ovarian cancer (Z80.41). Three relatives with ovarian cancer and Ashkenazi Jewish ancestry raise the chance of an inherited variant. A negative result in her would not end the need for advice for her relatives, since none of the affected relatives was tested. [S]
Data reviewed: Dr. Marchand's intake note. CA-125 1240 U/mL and CEA 1.6 ng/mL. Transvaginal ultrasound: a 9.2 cm solid and cystic right adnexal mass and a 5.1 cm solid left adnexal mass with internal blood flow, and moderate ascites (O-RADS 5). CT of the chest, abdomen and pelvis: bilateral adnexal masses, moderate ascites, omental caking up to 4 cm, a 1.2 cm right hemidiaphragm nodule and small pelvic peritoneal nodules; no enlarged lymph nodes, no liver or lung lesion, no pleural effusion. Omental core biopsy: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant, CK7 positive and CK20 negative. Hemoglobin 12.4 g/dL, platelets 412, creatinine 0.72 mg/dL, albumin 3.6 g/dL. [S]
Plan of Treatment
- Primary cytoreductive surgery in one week, aiming for no visible residual disease. [S]
- Genetic counseling and a germline multigene panel today (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes); tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency on the surgical specimen; a family letter offering cascade testing to blood relatives if a germline variant is found. [S]
- Hepatitis B, hepatitis C and HIV screening before chemotherapy. [S]
- Carboplatin AUC 5 and paclitaxel 175 mg/m2 every 21 days for six cycles, starting about three weeks after surgery, with a three-drug antiemetic regimen; blood counts, kidney function and magnesium before each cycle; CA-125 before each cycle; neuropathy checks before each paclitaxel dose; CT at the end of treatment. [S]
- Maintenance after a complete or partial response chosen from the genetic results: olaparib for two years if a BRCA1 or BRCA2 variant is found in the blood or tumor, with a monthly blood count. [S]
- Enoxaparin 40 mg daily for four weeks after surgery. [S]
- Distress screening at each visit, a cancer support community group, plain written information, and a discussion of surgical menopause and its management after the operation. [S]
- Discussed with Dr. Marchand, who saw her the same day. The images and biopsy were explained to Ms. Radner, who chose surgery next week; she decides who else receives this note. [S]
- Follow-up: Surgery in one week; gynecologic oncology review after the pathology and before each cycle; Dr. Marchand continues primary care and shares the monitoring. [S]